drugset / Trial / NCT03802747
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable colorectal cancer.
Timeline
- Start
- 2019-08
- Primary completion
- 2023-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |